For our next talk, in the Digital Phenotyping seminar series, we will hear from Professor Derek Hill, Professor of Digital Health at UCL in London, England, and also CEO of Panoramic Digital Health in Grenoble France, on Wednesday 23 October, 2:00pm – 3:00pm, at the Big Data Institute (BDI).
Title: From big data to niche data: the challenge of minimizing sample size in clinical trials
Date: Wednesday 23 October 2024
Time: 2:00 pm – 3:00 pm
Venue: BDI/OxPop, Seminar Room 0; followed by refreshments in the atrium
About the speaker:
Derek Hill is Professor of Digital Health at UCL in London, England, and also CEO of Panoramic Digital Health in Grenoble France.
Derek has spent more than 25 years working in both academia and industry on innovative digital technologies that provide insights into disease progression and treatment response. His particular focus has been on technologies that can be used in research studies and clinical trials to enrich study populations, and measure treatment safety and clinically meaningful outcomes. Derek’s initial work was based on imaging biomarkers, but in the last 10 years has become focused on wearable digital health technologies. He has been involved in developing these technologies (both hardware and software) and deploying them in clinical studies from single centre studies – to global phase 3 trials, and also alongside marketed drugs. He has more than 200 journal publications in these areas. Current research interest is controlling variability in home-based measurements using wearable sensors, and combining data from wearable and environmental sensors to provide signatures of activities and behaviours in patients with chronic illness. He has a particular focus on measures of sleep, fatigue and mobility.
Derek Hill was a member of Prime Minister David Cameron’s Research Champion Dementia group, chaired by Sally Davies and Mark Walport, was a member of the executive committee of the Dementia Platform UK, and a member of the RCUK Data to Early Diagnosis and Precision Medicine (D2EDPM) Advisory Board.
A key challenge in this field is providing the evidence to demonstrate to regulators that data from these technologies have the necessary performance to be used as part of regulatory submissions of new drugs. This is closely related – but not the same – as the regulatory process needed to show that these technologies can be used in medical devices to manage patients.
Derek has interacted with regulators on these topics for nearly 15 years, including in the qualification of imaging biomarkers for enriching clinical trials in Alzheimer’s disease and Parkinson’s disease (with the C-Path consortium), and also on protocol specific meetings with regulators around wearable technologies to capture such concepts of interest as mobility and sleep (both with individual companies and through consortia).
—————————————————————————————————————————————————————————————————————————-
Hybrid Option:
Please note that these meetings are closed meetings and only open to members of the University of Oxford. Please respect our speakers and do not share the link with anyone outside of the University. The purpose of these seminars is to foster more communication among employees throughout the University, so we strongly advise in-person attendance whenever feasible.
Microsoft Teams meeting
Join the meeting now
Meeting ID: 375 568 367 646
Passcode: 49cRyJ
——————————————————————————————————————————————————————————————————————————
If you wish to know more or receive information related to trainings and events at BDI, please subscribe by emailing bdi-announce-subscribe@maillist.ox.ac.uk. You’ll then receive an email from SYMPA and once you reply you’ll be on the list!
